[LupusDoc]

Ну так давайте обратимся куда обычно, т.е. в PubMed:

Microscopic hematuria was the most frequent (20%) adverse clinical event, but was unrelated to the INR. Three patients required discontinuation of therapy because of bleeding events (persistent hematuria and epistaxis).
[Ссылки доступны только зарегистрированным пользователям ]

We evaluated 29 consecutive patients in whom gross or microscopic hematuria developed while they were on heparin or warfarin anticoagulant therapy. Patients who had bleeding as a result of anticoagulant overdosage and/or from an additional organ system(s) other than the urinary tract were excluded from this review. Significant pathological findings consisting of carcinoma, calculi, renal infarction, infection, benign prostatic hyperplasia and/or adult polycystic renal disease were identified in 17 patients. Insignificant or incidental pathological findings classified as posterior urethritis, simple renal cyst or renal scarring were noted in 6 patients. No pathological condition was found in the remaining 6 patients. We conclude that a thorough and appropriate evaluation of the urinary tract should be conducted in patients on anticoagulant therapy who have gross or microscopic hematuria, since a pathological lesion of variable clinical significance often is discovered.
[Ссылки доступны только зарегистрированным пользователям ]

Coumadin-induced renal and retroperitoneal hemorrhages are rare.
[Ссылки доступны только зарегистрированным пользователям ]

The occurrence of occult bleeding in faeces and urine was a temporary phenomenon in most patients. Only macroscopic bleedings during these treatment modalities were of clinical importance, and screening for occult bleeding was of limit value.
[Ссылки доступны только зарегистрированным пользователям ]

Timely and thorough evaluation of hematuria in patients taking anticoagulants is necessary to identify and treat clinically important pathology.
[Ссылки доступны только зарегистрированным пользователям ]

Ну и т.д.
Надо, конечно, обследовать пациентку на предмет сопутствующей патологии мочевыводящей системы, но это не основание для немедленного прекращения антикоагуляции и подвергания пациента риску тромботических осложнений. Особенно, учитывая многолетний анамнез приема антагонистов витамина К.